WebJun 8, 2024 · Cisplatin, the active ingredient in Cisplatin injection, is a yellow to orange crystalline powder with the molecular formula Cl 2 H 6 N 2 Pt and a molecular weight of 300.05. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. WebAbstract Cisplatin is a widely used platinum‐based chemotherapy agent. Its common adverse effects are neuropathy, nephrotoxicity, electrolyte abnormality, and rarely causing thrombotic vascular toxicity. We present a patient known to have small‐cell lung cancer who developed ischemic cerebrovascular accident (CVA) after receiving ...

NCBI Bookshelf

WebMay 7, 2024 · For the approximately 30% of patients with SCLC who have limited-stage disease at the time of diagnosis (ie, tumors confined to the hemithorax of origin, the … WebNational Center for Biotechnology Information novas headed paper

Electrolyte disorders with platinum-based chemotherapy ... - PubMed

WebJun 24, 2024 · Cisplatin-induced nephrotoxicity mainly manifests as kidney tubular injury leading to electrolyte disturbances manifested as hypomagnesemia, hypokalemia, and hypophosphatemia and/or increased serum creatinine (occurring more than 7 days after treatment initiation) and decreased glomerular filtration rate [ 8, 9 ]. WebMay 18, 2024 · Compared with young patients, the incidences of cisplatin-induced nephrotoxicity and acute kidney injury (AKI) in elderly patients are significantly increased, … WebFrequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%. how to soften chicken meat